Skip to content

Clinical trials

Dwarfism trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Dwarfism Country / region: United States Clear all

55 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20042
20056
20061
20071
20082
20091
20102
20111
20122
20131
20142
20151
20162
20171
20183
20194
20204
20212
20221
20232
20244
20253
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed31
Terminated7
Recruiting6
Active, not recruiting6
Enrolling by invitation3
Unknown status1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
BioMarin Pharmaceutical9
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)7
QED Therapeutics, a BridgeBio company7
Nemours Children's Clinic5
Ascendis Pharma A/S3
Children's Hospital Medical Center, Cincinnati2
Massachusetts General Hospital2
National Human Genome Research Institute (NHGRI)2
Nationwide Children's Hospital2
Andrew Dauber1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Dwarfism55
Achondroplasia17
Bone Diseases16
Musculoskeletal Diseases14
Genetic Diseases, Inborn12
Osteochondrodysplasias12
Mucopolysaccharidosis IV11
Dwarfism, Pituitary9
Bone Diseases, Developmental8
Failure to Thrive4

Trials

Showing 1 to 25 of 55. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.